Novo Nordisk’s ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025.
Where Today's News Shapes Tomorrow
March 5, 2026
Headlines
